We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Expert Panel Gives Mixed Reviews of Opioid Treatment for Depression
FDA Expert Panel Gives Mixed Reviews of Opioid Treatment for Depression
An FDA advisory panel Thursday voted against the effectiveness and benefit-risk profile of Alkermes’ NDA for buprenorphine/samidorphan to treat major depressive disorder but in favor of its safety.